Has David Shaw, MD received payments from drug or device companies?

Yes. Drug and device makers reported $428 in general payments to David Shaw, MD across 62 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Shaw, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Shaw, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Shaw, MD

Psychiatry · Issaquah, WANPI 1003971904

Payments from drug & device makers

$428in general payments, 2019–2025

Across 62 payments — averaging $6.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$365
Alkermes, Inc.$31
Bausch Health US, LLC$19
Sunovion Pharmaceuticals Inc.$14

What the payments were for

Food & beverage$39893%
Education$307%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	58	$365
Alkermes, Inc.	2	$31
Bausch Health US, LLC	1	$19
Sunovion Pharmaceuticals Inc.	1	$14

How this compares

$428 in reported general payments places this provider in the 80th percentile of 576 psychiatry providers in Washington.

See all psychiatry providers in Washington →

Medicare billing

Part B allowed, 2024

$176,774

Medicare patients

Services billed

1,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	157	$5,709
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	24	$3,622
Olanzapine	159	$3,226
Clonazepam	328	$3,219
Quetiapine Fumarate	117	$2,324
Trazodone Hcl	200	$2,086
Bupropion XlBupropion Hcl	139	$2,038
Gabapentin	75	$2,014
Fluoxetine Hcl	114	$1,861
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	50	$1,811
Aripiprazole	49	$1,788
Desipramine Hcl	39	$1,751
Duloxetine Hcl	51	$1,265
Lamotrigine	81	$1,211
Alprazolam	209	$1,135

Paid to pharmacies, not to this prescriber.

Other psychiatry in Issaquah

Arifulla KhanBellevue$35.6M
Arun AroraBellevue$10.6M
Jeffrey HansenVancouver$2.8M
Chester RobachinskiSeattle$1.1M
Larry BornsteinEverett$663K
David DunnerMercer Island$649K
Matthew BogoyasYakima$500K
Aishwarya PrasadBellevue$323K
Shirin SchillingEverett$263K
Pablo ProanoSeattle$112K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →